Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Genome-scale discovery of renal cell carcinoma vulnerabilities during metabolic stress using a second-generation CRISPR-Cas9 library.
EF 2015-16
Résumé
Like all cells, cancer cells require basic nutrients such as glucose and amino acids to survive. However, as cancer cells divide at faster rates than normal cells their demand for these basic nutrients is greatly increased, resulting in a nutrient scarce microenvironment. To survive in this environment, cancer cells alter the molecular machinery that regulates the chemical reactions required to utilize nutrients as fuel. This process is known as metabolic reprogramming, and is a fundamental hallmark of cancer. For decades, scientists have tried to exploit these molecular changes by developing therapies that specifically target cancer metabolic reprogramming by imposing additional metabolic stress. While promising, it is now evident that cancer cells have learned to "adapt" to this type of therapy, resulting in treatment resistance and relapse. Kidney cancer has historically been one of the most treatment resistant malignancies, and recent evidence suggests that metabolic reprogramming and adaptation are drivers for poor survival outcomes. To date, the molecular mechanisms that allow kidney cancer cells to adapt to therapy induced metabolic stress remain elusive. Here, we propose to utilize a novel genetic technology to systematically study which genes are necessary for kidney cancer adaptation to metabolic stress. This technology allows us to interrogate the entire human genome simultaneously, providing a previously unimaginable view of this process. Once we determine the "essential gene set" required for cancer cell metabolic adaptation, we will devise therapies that specifically block adaptation. These therapies will be combined with existing metabolic stress agents (currently used to treat kidney cancer) as a new treatment strategy. This work will employ clinically relevant cancer models derived from surgical tumor specimens ensuring the rapid translation of our findings to clinical trials to improve the currently abysmal survival outcomes of patients.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
339605
Name
Lawson Keith A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Genome-scale discovery of renal cell carcinoma vulnerabilities during metabolic stress using a second-generation CRISPR-Cas9 library.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Drug Development; Functional Genomics; Kidney Cancer; Metabolism; Patient-Derived Xenograft; Translational
Abstract
Like all cells, cancer cells require basic nutrients such as glucose and amino acids to survive. However, as cancer cells divide at faster rates than normal cells their demand for these basic nutrients is greatly increased, resulting in a nutrient scarce microenvironment. To survive in this environment, cancer cells alter the molecular machinery that regulates the chemical reactions required to utilize nutrients as fuel. This process is known as metabolic reprogramming, and is a fundamental hallmark of cancer. For decades, scientists have tried to exploit these molecular changes by developing therapies that specifically target cancer metabolic reprogramming by imposing additional metabolic stress. While promising, it is now evident that cancer cells have learned to "adapt" to this type of therapy, resulting in treatment resistance and relapse. Kidney cancer has historically been one of the most treatment resistant malignancies, and recent evidence suggests that metabolic reprogramming and adaptation are drivers for poor survival outcomes. To date, the molecular mechanisms that allow kidney cancer cells to adapt to therapy induced metabolic stress remain elusive. Here, we propose to utilize a novel genetic technology to systematically study which genes are necessary for kidney cancer adaptation to metabolic stress. This technology allows us to interrogate the entire human genome simultaneously, providing a previously unimaginable view of this process. Once we determine the "essential gene set" required for cancer cell metabolic adaptation, we will devise therapies that specifically block adaptation. These therapies will be combined with existing metabolic stress agents (currently used to treat kidney cancer) as a new treatment strategy. This work will employ clinically relevant cancer models derived from surgical tumor specimens ensuring the rapid translation of our findings to clinical trials to improve the currently abysmal survival outcomes of patients.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lawson, Keith A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~